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Private practice perspective on conflict of
interest mandates
Russell H. Samson, MD, FACS, RVT, Sarasota, Fla
This article assesses the current mandates on conflict of interest issues as they affect the practice of community-based
vascular surgery and the pharmaceutical and medical technology industries and expresses the views of a private practice
vascular surgeon. Scenarios where conflict of interest may occur are presented with assessments on how these scenarios
will play out if such mandates are enforced. (J Vasc Surg 2011;54:15S-8S.)
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rAt the 2010 VASCULAR meeting in Boston, large
signs informed attendees that physicians practicing in Mas-
sachusetts or Vermont were prohibited by state law from
partaking of food or drink provided by the exhibitors. This
was the result of recent state legislation that seeks to pre-
vent a conflict of interest by limiting the interaction be-
tween physicians and the pharmaceutical and medical
equipment industries.
The term “conflict of interest” will be referred to many
times in this publication. Within the context of the current
article, the term implies that the relationship of a private
practice vascular surgeon with industry or its representa-
tives will result in clinical decisions that negatively affect
patient care. Some of the interactions between industry and
private surgeons that have been identified as possibly result-
ing in such conflict of interest include funding for travel
expenses to educational events or corporate headquarters,
payment to traveling mentors, promotional gifts, payment
for speaking on behalf of the company or its products, the
presence of a sales representative in the operating room or
angiography suite, the provision of free lunch for the doc-
tor or doctor’s staff, the provision of drug samples, consult-
ing fees, payment for (including to patients) research pro-
tocols, and assistance in marketing the surgeon to referring
physicians or the lay public.1-14
Although arguments can be made for and against these
practices, state and federal mandates, as well as medical
society and industry codes of ethics, have already been
promulgated to prevent many of these activities. Scenarios
where conflict of interest can occur will be presented to
provide a community practice surgeon’s perspective on
how these conflict of interest mandates will affect the
private practice of vascular surgery.
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Industry representatives in the surgeon’s office.
he relationship between sales representatives and physi-
ians that occurs in the physician’s office has been especially
riticized for its potential to cause a conflict of interest. This
an result from inordinate sales pressure, presentation of
he benefits of a drug or technology without providing
egative aspects, the opportunity to supply gifts and pro-
otional items such as pens, coffee cups, and notepads, and
he provision of free lunch to the surgeon and staff. Some
ave suggested that the personal relationships that develop
etween the doctor and representatives may bias clinical
ecisionmaking. Accordingly, the newmandates and codes
f ethics restrict industry’s access to, and relationship with,
he surgeon in the surgeon’s office.
Multiple publications and research analyses have at-
empted to define the conflict of interest risk of such
arketing practices. In 2004, pharmaceutical companies
pent $57.5 billion on promotion in the United States
lone.2 This represented 27.4% of their revenue. Wazana1
eported in 2000 that $11 billion was spent each year by
harmaceutical companies in promotion andmarketing, $5
illion of which went to sales representatives. To identify
he extent of and attitudes toward the relationship between
hysicians and the pharmaceutical industry and its repre-
entatives, and its effect on the knowledge, attitudes, and
ehavior of physicians, Wazana reviewed 538 studies but
ound only 16 that offered sufficient information.
Certain findings from that review, as well as more
ecent research, warrant discussion. Notably, physicians
elieved that representatives provided accurate information
bout their drugs, yet were equivocal in their beliefs that
epresentatives could provide accurate information on es-
ablished or alternative drugs. Most also believed that rep-
esentatives would prioritize product promotion above pa-
ients’ welfare, evidence of healthy skepticism among these
hysicians. This would tend to negate the argument that
octors would naively accept the representative’s sales
itch.
The Wazana1 review found that interactions with phar-
aceutical representatives affected the prescribing practice
n cost, nonrational prescribing, awareness, preference, and
apid prescribing of new drugs, and decreased prescribing
f generic drugs. Some of these practices patterns will be
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September Supplement 201116S Samsondetrimental to public health; however, the rapid introduc-
tion of new medications can be beneficial, and in some
instances, underprescribing medications can be more det-
rimental than overprescribing. For example, as it applies to
vascular surgery, underprescription of statins and antihy-
pertensives has had a negative effect on patient care.3
The provision of free samples of a drug has been
associated with a preference for and rapid prescription of
that drug.4 Accordingly, many pharmaceutical companies
no longer offer such samples. This can have unfortunate
repercussions. The ability to provide a few sample pills can
allow the surgeon to evaluate potential side effects, thus
saving the patient from the unnecessary expense of filling a
3-month prescription. More importantly, not providing
samples can delay the patient’s access to that medication in
some instances. For example, vascular surgeons commonly
use samples to initiate an antiplatelet agent in someone at
risk for stroke, or with a newly implanted stent, or to
provide a statin to a patient with advanced atherosclerotic
disease.
Whether the practice of providing promotional items
influences a surgeon’s choice of technology or pharmaceu-
tical agents is now moot, because it has almost completely
been abolished by governmental restriction as well as ethi-
cal codes promulgated by the pharmaceutical and medical
technology industry. The provision of free lunch to the
surgeon and the surgeon’s staff in association with a sales
presentation has also been severely restricted by legislation,
based on the argument that it represents an inducement.
Unfortunately, lunchmay be the only time that the surgeon
will have time to meet with the representative.
The educational value of such lunch meetings has also
been challenged. From a review of personal experience as
well as a MEDLINE search from January 1966 to May
1996, Lexchin5 suggested that sales representatives pre-
sented only selected, usually positive, information about
their products. Two other reviews have presented data
showing an independent association between physicians
receiving sponsored meals and making subsequent formu-
lary addition requests for drugs that were detailed during
those meals.6,7 However, neither of these reports provided
information on whether such formulary requests were ap-
propriate or inappropriate. Further, in a more recent review
of all publications dealing with direct pharmaceutical pro-
motion to physicians, the authors reported that they were
unable to reach any definitive conclusions about the degree
to which information from pharmaceutical companies in-
creases, decreases, or has no effect on the frequency, cost,
or quality of prescribing.8
Vascular surgeons not only prescribe medications but
also use many different technologies, most of which con-
tinue to evolve rapidly. They not only operate but also
medicate and dilate. They not only use needle and thread
but also a vast array of devices and medications that un-
dergo constant development and improvement. It is imper-
ative that vascular surgeons have access to information
about these new treatment options. In many instances this
information can be readily obtained by meeting with indus- fry representatives in the surgeon’s office during lunch. It
an be assumed that some presentations will be biased, and
t is expected that the surgeon will keep an open mind
bout the information that is provided. The value of that
eeting will accordingly vary. Conflict of interest can only
e suggested if the lunch was provided free by the sales
epresentative. Some surgeons will therefore choose not to
eceive complimentary food, while others will accept the
unch without regarding it as an inducement to use the
evice or drug. Meeting with representatives from compet-
tive companies increases the educational opportunity and
ecreases the possibility of conflict of interest. The relation-
hip that develops between the sales representative and the
hysician may indeed result in a positive attitude toward
hat representative.9,10 This is not necessarily a negative,
owever. Inmany instances, specifically in the device indus-
ry, these sales representatives are the same individuals who
an be of help in the operating room or angiography suite
see below).
Industry representatives in the operating room or
ngiography suite. The presence of an industry represen-
ative in the operating room or angiography suite has been
riticized as exerting undue influence on the choice of
echnology being used by the surgeon. In the past, where
hese industry representatives were allowed free access to
he suites, such influence could have occurred. However, in
ost institutions industry representatives can now only
nter the operating or angiography suite when a procedure
sing that representative’s technology is being performed
nd at the direct request of the surgeon. Under such
ircumstances, the decision to use that technology has
lready been made and thus is not influenced by the pres-
nce of the representative. Despite this, the presence of an
ndustry representative in the suite is still viewed negatively
y some, resulting in the development and enforcement of
estrictions to this practice. In many instances, however,
ndustry representatives can be critical to the performance
f the procedure. They have often witnessed a large num-
ers of the procedure(s) being performed by the surgeon
nd, as a result, their experience can prove invaluable when
nusual circumstances arise. They also provide the oppor-
unity to educate the nursing and ancillary staff about their
evices. The American College of Surgeons (ACS) has
upported industry representatives in the operating room,
rovided that certain guidelines are followed:
The ACS recognizes the need for a structured system
within the perioperative setting for education, training,
and introduction of procedures, techniques, technology,
and equipment to the surgical health care team. Health
care industry representatives (HCIR), by virtue of their
training, knowledge, and expertise, can provide technical
assistance to the surgical team, which expedites the pro-
cedure and facilitates the safe and effective application of
surgical products and technologies.11
Funding for traveling to educational events. Funding
or industry-supported travel is being severely restricted.
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Volume 54, Number 18S Samson 17SHowever, ongoing education regarding new medications
and devices is necessary for their safe and effective use.
Accordingly, it is imperative that the vascular surgeon be
exposed to this information in as many settings as possible.
These venues include regional and national society meet-
ings, industry-supported continuing medical education
events, and corporate headquarters where devices are con-
structed. It is reasonable to suggest that industry support of
travel to society meetings should be considered as an in-
ducement to use that company’s products. However, it
should be regarded as appropriate that travel expenses be
paid if a surgeon is required to travel to gain experience
with a device that he or she will be using for bona fide
reasons. Legislation that prohibits such reimbursement and
further restricts the provision of free food at company
headquarters should not be supported. Legislation pre-
venting payment for time away from the surgeon’s practice
is, on the other hand, appropriate.
Payment to traveling mentors. Some surgeons may
develop extensive experience with a particular device. As
such, industry may turn to those surgeons for help in
training other users of their product. It is appropriate for
those surgeons to be compensated for their travel expenses
and for their expertise, despite contrary recommendations
by some professional societies. Similar programs are avail-
able for other health professionals and have been endorsed
by their national societies. For example, the Association of
Operating Room Nurses offers free industry-supported
training programs for their members.12 Failure to compen-
sate these surgeons will essentially destroy mentoring pro-
grams. Because most surgeons do not have the time or the
financial resources to travel to witness procedures at other
institutions, these restrictions on mentoring will negatively
impact surgical training and the ability to provide up-to-
date care.
Payment for speaking on behalf of a company’s
product. Industry has often turned to and compensated
private practice vascular surgeons to give educational talks
to other physicians and the lay public concerning their
product. Because the surgeons have to take time away from
their practices to prepare and give the talks, it would seem
appropriate that they be compensated. However, this prac-
tice is also being restricted because it is seen as an induce-
ment for that surgeon to use the company’s products. It has
also been questioned whether such promotional talks ben-
efit patient care. Some even find it inappropriate that the
company provides the speaker with promotional slides.13
Such speaking activities can be beneficial, however.
They provide an opportunity for private practice vascular
surgeons to increase their visibility in the local community.
They bring expert speakers to rural or underprivileged areas
that otherwise would be underserved by medical education
opportunities. Such lectures can inform physicians in other
specialties about advancements in the field of vascular sur-
gery to which they would not have otherwise been exposed.
It has also never been shown that such presentations have a
negative impact on patient care. Mandates against such ipeaking arrangements will negatively impact the spread of
aluable information.
Consulting fees. The rapid advancement of medical
cience and technology has occurred because of the close
elationship between industry and physicians. In return for
heir help in the development and use of devices, corpora-
ions will pay vascular surgeons consulting fees. Conflict of
nterest arises when such fees are disproportionate to the
alue of the information provided by the surgeon. The new
ederal legislation will provide the public with information
bout these payments as well as all other payments in
oney or kind to or on behalf of the surgeon. Such
atabases are already in place in states such asMassachusetts
nd Vermont.
How this information will affect the relationship be-
ween the patient and their surgeon remains to be seen. It is
onceivable that many patients will not be able to evaluate
hese data because in most cases it requires some computer
kills that may not be available to them. Further, the
resentation of data in these spreadsheets can be confusing,
nd patients may not be able to differentiate appropriate
ompensation for payments such as royalties from less
appropriate” monies spent on food. As a result, it is
ossible that a patient may incorrectly lose faith in his or her
urgeon.
Private practice surgeons will more likely be listed on
hese databases than their colleagues in academic institu-
ions because of industry support to academic surgeons
hrough “donations” to institutions, medical schools,
oundations or hospitals rather than directly to the aca-
emic surgeon. The operative concept is that the head of an
cademic department or hospital would “manage” the
unds, thus saving the individual academic surgeon from
otential conflicts of interest. The likelihood that this has
lready occurred is shown by a review of the database
rovided by Massachusetts. In 2009, the pharmaceutical
nd technology industries provided $3,885,371 to Massa-
husetts General Hospital; $923,493 to Brigham and
omen’s Hospital; $687,148 to Beth Israel Deaconess
edical Center; and $386,788 to Tufts Medical Cen-
er.14 Despite the large number of notable academic
ascular surgeons in these institutions, most were not
eported to have received any payments and the few that
ere listed were shown to have received only minimal
mounts, usually $200.
Financial assistance in practice marketing. Many
urgeons now find it essential to market their practice to
eferring physicians and the lay public. Corporate sponsor-
hip of such marketing has been used to offset associated
osts. Certainly, conflict of interest can arise from such
upport and so care should be taken to determine the
ppropriateness of such behavior.
Payment for including patients in research
rotocols. Private vascular surgeons are often requested
o include their patients in clinical trials. In return, com-
ensation has been offered. This practice has been correctly
ondemned. However, if the surgeon is actively participat-
ng in the trial and such activity requires extra work, it is
11
1
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work. Failure to allow such compensation will result in
fewer patients being entered into trials from community
practice situations where real-world experience can provide
valuable information for those trials.
CONCLUSIONS
Most of the scenarios that have been presented here
could equally occur in an academic vascular practice. How-
ever, current conflict of interest mandates may have more
serious consequences for private practice surgeons than
those employed by medical schools or hospitals. This will
occur as a result of industry shifting support from individual
surgeons to those institutions (and thus indirectly to those
institutions’ employed surgeons). Thus, many private prac-
tice surgeons will find less opportunity for educational
experiences, less support in the operating room, decreased
ability to bring new technologies into their practices, in-
creasing distrust by the lay public, and more competition
from hospitals, medical schools, and institutionalized med-
icine. In the end, it may be their patients that suffer the
most.
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